TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04497220

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Negative Connotation Langauge
Description: The study intervention consists of two separate scripts read to the patient by the anesthesiologist performing their labor epidural. The control script includes language containing the wording Poke and a burn said prior to numbing medication for the epidural procedure. There will be no difference in the epidural placement, medications, or the rest of the script.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Connotation Language
Description: The study intervention consists of two separate scripts read to the patient by the anesthesiologist performing their labor epidural. The experimental script includes language containing the wording this is numbing medication, which will make the rest of the procedure go easier said prior to numbing medication for the epidural procedure. There will be no difference in the epidural placement, medications, or the rest of the script.
Study: NCT06780566

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Point-of-care PCR testing for respiratory viruses
Description: A nasal swab will be collected by trained research staff in full personal protective equipment (PPE) and placed into 3 mL of viral transport medium. The sample will be immediately processed and analysed in the ED using the Xpert® Xpress SARS-CoV-2/Flu/RSV test according to the manufacturer's instructions. The results of the test will be documented in the patient's paper or electronic case notes, and the clinical team will be directly informed of all results. The participant or legal guardian who signs the consent form will also be informed of the results when appropriate.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Laboratory PCR testing for respiratory viruses
Description: The ordering of test for respiratory pathogens will be decided by the treating clinical team. All tests will be performed using the standard methods of the hospital laboratory.
Study: NCT06781021

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tourniquet
Description: In all cases the application of a pneumatic torniquet will be applied to the proximal thigh after induction of anesthesia but will not be inflated for the group receiving TXA.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tourniquet
Description: In all cases the application of a pneumatic torniquet will be applied to the proximal thigh after induction of anesthesia but will not be inflated for the group receiving TXA.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TXA
Description: In all cases the application of a pneumatic torniquet will be applied to the proximal thigh after induction of anesthesia but will not be inflated for the group receiving TXA.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TXA
Description: In all cases the application of a pneumatic torniquet will be applied to the proximal thigh after induction of anesthesia but will not be inflated for the group receiving TXA.
Study: NCT06781255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kamuvudine-9
Description: 96 mg tablets taken twice a day for 4 weeks
Study: NCT06779890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane will be administered at concentrations maintaining MAC= 0.8 for the first 60 minutes , MAC=1.2 for the next 60 minutes and MAC= 0.8 until surgery completion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane will be administered at concentrations maintaining MAC= 0.8 for the first 60 minutes , MAC=1.2 for the next 60 minutes and MAC= 0.8 until surgery completion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Desflurane will be administered at concentrations maintaining MAC= 0.8 for the first 60 minutes , MAC=1.2 for the next 60 minutes and MAC= 0.8 until surgery completion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: Desflurane will be administered at concentrations maintaining MAC= 0.8 for the first 60 minutes , MAC=1.2 for the next 60 minutes and MAC= 0.8 until surgery completion.
Study: NCT06780423

Intervention type: PROCEDURE
Intervention: Minimal invasive fine needle muscle biopsies
Description: Fine needle muscle biopsies will be taken from the m. erector spinae and the m. vastus lateralis. Participants are placed in a standardized prone position on the examination table for measurements of the m. erector spinae and in a supine position for measurements of the m. vastus lateralis.

Intervention type: PROCEDURE
Intervention: Minimal invasive fine needle muscle biopsies
Description: Fine needle muscle biopsies will be taken from the m. erector spinae and the m. vastus lateralis. Participants are placed in a standardized prone position on the examination table for measurements of the m. erector spinae and in a supine position for measurements of the m. vastus lateralis.

Intervention type: PROCEDURE
Intervention: Minimal invasive fine needle muscle biopsies
Description: Fine needle muscle biopsies will be taken from the m. erector spinae and the m. vastus lateralis. Participants are placed in a standardized prone position on the examination table for measurements of the m. erector spinae and in a supine position for measurements of the m. vastus lateralis.
Study: NCT06782308

Intervention type: OTHER
Intervention: Survey using a questionnaire.
Description: patients preferences survey
Study: NCT06772688

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: orthognathic surgery
Description: Maxillary repositioning and fixation with custom made plate
Study: NCT06774378

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minds@Work-ADHD-Quality of Life
Description: Minds@Work-ADHD-Quality of Life

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Minimal contact
Description: Weekly 15-minute scripted phone calls made individually by a member of the research team to offer minimal support, without any active intervention.
Study: NCT06782191

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic lysis and lavage
Description: Arthroscopic lysis and lavage refers to an arthroscopic procedure where the temporomandibular joint is rinsed with saline solution and where the joint capsule is distended and where adhesions are lysated bluntly.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Operative arthroscopy
Description: Operative arthroscopy refers to an arthroscopic procedure where the temporomandibular joint is accessed via two ports of entry. The joint is rinsed with saline solution and the anterior disc attachment is released with cold ablation where after the posterior attachment is sclerosed with the coagulation mode on the coblator.
Study: NCT06781892

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anterior-lateral pad positioning
Description: Defibrillation pads positioned anterior-lateral

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anterior-posterior pad positioning
Description: Defibrillation pads positioned anterior-posterior
Study: NCT06735625

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Measurement of AHSP concentration
Description: Pseudonymization and identification of research samples EDTA tube of 4 mL for patients over 15 and a half years old, and 2 EDTA tubes of 2 mL for children aged 3 to 15 and a half years, totaling 4 mL) by Team 4 according to the procedure in force at the URC.~The 4 mL research sample will then be divided into 1 mL fractions by a technician in the laboratory and stored at -80°C in the medical biology laboratory.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Measurement of AHSP concentration
Description: Pseudonymization and identification of research samples EDTA tube of 4 mL for patients over 15 and a half years old, and 2 EDTA tubes of 2 mL for children aged 3 to 15 and a half years, totaling 4 mL) by Team 4 according to the procedure in force at the URC.~The 4 mL research sample will then be divided into 1 mL fractions by a technician in the laboratory and stored at -80°C in the medical biology laboratory.
Study: NCT06781892

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Double-sequential defibrillation
Description: Combination of anterior-lateral and anterior-posterior pad positioning for a total of 4 pads and 2 shocks.
Study: NCT06781827

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The experimental phase of the study lasts 8 weeks and each patient will be visited 4 times (January, March, June, and December).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: The experimental phase of this study had last 8 weeks and each patient will make 4 visits (January, March, June, and December).
Study: NCT06735625

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measurement of AHSP concentration
Description: Pseudonymization and identification of research samples EDTA tube of 4 mL for patients over 15 and a half years old, and 2 EDTA tubes of 2 mL for children aged 3 to 15 and a half years, totaling 4 mL) by Team 4 according to the procedure in force at the URC.~The 4 mL research sample will then be divided into 1 mL fractions by a technician in the laboratory and stored at -80°C in the medical biology laboratory.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measurement of AHSP concentration
Description: Pseudonymization and identification of research samples EDTA tube of 4 mL for patients over 15 and a half years old, and 2 EDTA tubes of 2 mL for children aged 3 to 15 and a half years, totaling 4 mL) by Team 4 according to the procedure in force at the URC.~The 4 mL research sample will then be divided into 1 mL fractions by a technician in the laboratory and stored at -80°C in the medical biology laboratory.
Study: NCT06745479

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Emotion Upregulation
Description: Participants will identify personal goals or activities that they would like to engage in more and describe these goals/activities in a written format with research staff. Participants will then complete a gambling task during functional MRI scanning. Prior to making some gambling decisions, participants are instructed to mentally imagine achieving a goal or engaging in an enjoyable activity. Prior to the other decisions participants are instructed to respond naturally (i.e., not use the cognitive strategy).
Study: NCT06745102

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Xanthohumol
Description: Participants receive a study drink supplemented with Xanthohumol (0 mg = Placebo or 0.75 mg soluble Xanthohumol)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iso-alpha Acids
Description: Participants receive a study drink supplemented with Iso-alpha Acids (0 mg = Placebo or 45 mg Iso-alpha Acids)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Xanthohumol + Iso-alpha Acids
Description: Participants receive a study drink supplemented with Xanthohumol and Iso-alpha Acids (0 mg = Placebo or 0.75 mg + 45 mg soluble Xanthohumol + Iso-alpha Acids)
Study: NCT06744322

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fast discharge strategy
Description: Patients undergoing invasive management after myocardial infarction will be discharged after 24 (+/- 12) hours.
Study: NCT06745934

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Minds Program
Description: Participants in this arm engage with the Healthy Minds Program app/
Study: NCT06743867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pressurized Intraperitoneal Aerosol Chemotherapy
Description: The comprehensive therapeutic strategy will be modified based on the integrated 2- or 3-week systemic chemotherapies. In the interim, a total of three PIPAC procedures will be conducted for all qualifying patients.~1. PIPAC combined with 2-week systemic chemotherapies:~   PIPAC therapy will occur every four weeks, while systemic chemotherapies will be administered during the first and third weeks following the initial and second PIPAC procedures respectively.~2. PIPAC combined with 3-week systemic chemotherapies:~(1) Scheme 1: PIPAC therapy will occur every 6 weeks, with systemic chemotherapies administered during the 1st and 4th weeks following the first and second PIPAC procedures, respectively.~(2) Scheme 2: PIPAC therapy will occur every 6 weeks, while systemic chemotherapies will be administered in the 2nd and 5th weeks following the initial and second PIPAC procedures, respectively.
Study: NCT06745713

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Turkish- Computer System Usability Questionnaire Short Version
Description: Developed in 1995 by Lewis at IBM, the Computer System Usability Questionnaire (CSUQ) is one of the widely used questionnaires in the field of usability. The scale, which was adapted into Turkish by Erdinç in 2013, consists of 13 items in total. It has 4 sub-dimensions: system usefulness (items 1-6), information quality (items 7-9), interface quality (items 10-12) and general satisfaction (item 13). Each item is scored as 1 (Strongly agree) - 7 (Strongly disagree). The Cronbach α of the scale is \> .70 and the Cronbach α value for each sub-dimension varies between .73 and .92. A minimum score of 13 and a maximum score of 91 can be obtained from the scale. A low score is defined as good usability, and the higher the score, the lower the usability quality of the system (Erdinç \& Lewis, 2013).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Student Information Form
Description: In the form developed by the researchers in line with the literature, a total of 12 questions were included to determine the socio-demographic characteristics of the students (such as age, gender, academic average, whether they provide care to patients with chest tubes, whether they receive training on chest tube care). All participants in the experimental and control groups were applied once as a pre-test.
Study: NCT06780982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balloon-Blowing exercise program
Description: he program begins with a one-on-one session on the first day of the research project and continues with home-based care through the LINE application on a smartphone for 5 weeks. The program consists of four steps:~1. Decision-Making in Self-Care~2. Setting Goals and Planning Self-Care~3. Self-Care Implementation: practicing the balloon-blowing exercise daily for 3 sets of 3 balloons per set (a total of 9 balloons/day), with a 1-minute rest between sets, over a period of 5 weeks.~4. Maintaining Self-Care Behaviors

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard nursing care
Description: The actions of nurses towards school-age children with obstructive sleep apnea at the hospital involve screening patient records and distributing educational materials in the form of brochures to individual pediatric patients and their parents. The knowledge provided in the brochures includes instructions on how to administer inhaled medication, avoiding allergens, performing facial and neck muscle exercises, and attending follow-up appointments as scheduled.
Study: NCT06782126

Intervention type: BEHAVIORAL
Intervention: BreeZe (Brandwonden en Zelfmanagement)
Description: BreeZe is a self-management support program designed to enhance burn survivors' intrinsic motivation and self-efficacy for self-management after discharge. The intervention is based on the Self-Regulation Theory framework. Key strategies include evidence-based techniques such as goal setting and pursuit, Solution-Focused Brief Therapy, and Motivational Interviewing. The program takes a positive approach to boost motivation and self-efficacy, promoting sustainable behavior change in burn aftercare. BreeZe will be implemented through various strategies, including educating healthcare professionals on self-management, training them in communication skills (e.g., motivational interviewing), and providing materials such as a decision aid tool (self-management web) and a workbook tailored to burn survivors. Burn survivors will use the web to identify and prioritize problems, set personalized goals with their healthcare professional, and create an action plan for goal attainment.
Study: NCT06780540

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Operation Alert: Support prgram
Description: Substudy 1:~Testing of a newly developed psycho-education tool will occur across four partner hospitals and participating nonprofit organizations (NGOs). Victims of violence seeking care at these sites will receive immediate support, with the pilot study integrated into standard care practices. The psycho-education toolkit enhances the foundational care already provided. The tool supports healthcare providers in offering psycho-education about e.g. violence and (the effects) of trauma, ...~Substudy 2:~This pilot study evaluates the Operation Alert guidelines within the geriatrics departments of four hospitals. A geriatric assessment is standard care during admission to these departments. The pilot will be embedded into this existing practice to ensure alignment with routine care. Additional questions will be embedded in a geriatric assessment/intake focusing on older adults' well-being, relationships and social network, and potential life events (e.g. experiences of violence).
Study: NCT06780930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorasidenib
Description: For oral administration once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For oral administration once daily
Study: NCT06782412

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]AlF-FAPI-74 PET/CT
Description: A \[18F\]AlF-FAPI-74 PET/CT will be performed at the same site of the screening visit (UZ Leuven, UZ Gent or UZ Antwerpen). Subjects are required to be sober four hours before the scan. The patient will get an IV line, through which the \[18F\]AlF-FAPI-74 will be injected in one bolus (3,5 MBq/kg). After 60 minutes, the acquisition on the PET/CT scan will take place. The CT will be a low dose CT with oral contrast. After the scan, participants will be observed at the department in case of adverse events. During this time, the participant can fill in the PRO. The estimated duration of this visit is three hours. If the patient receives neo-adjuvant therapy, a second \[18F\]AlF-FAPI-74 PET/CT will be performed maximum one month before surgery. If the planned surgery gets postponed after the second \[18F\]AlF-FAPI-74 PET/CT has been performed, we will have the possibility to perform one additional (i.e. third) \[18F\]AlF-FAPI-74 PET/CT, before the final surgery.
Study: NCT02380534

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: H.E.L.P. apheresis
Description: High cardiovascular risk patients will undergo H.E.L.P. apheresis procedure every 3 weeks for 1 year.
Study: NCT05390255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray hormone
Description: This group of patients received mometasone furoate nasal spray hormone treatment throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray hormone + oral hormone
Description: The patients in this group were given oral hormone therapy for 14 days in the first month and the fourth month under the background of mometasone furoate nasal spray hormone treatment throughout the course.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray hormone + omalizumab
Description: The patients in this group were injected with omalizumab once a month under the background of mometasone furoate nasal spray hormone treatment, for a total of 6 times.
Study: NCT06127186

Intervention type: DIAGNOSTIC_TEST
Intervention: Swab test for viral antigens
Description: No intervention except for a routine examination and viral testing is planned.
Study: NCT05895435

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: radiofrequancy
Description: * Power of device: 150 W~* Duration of the session: 40 minutes~* Frequency: 2 sessions per week for 8 week.~* Heating temperature: According to patient tolerance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: The program include five minutes for warming-up in the form of range of motion and stretching exercises, thirty minutes of walking on treadmill with high speed (60-70% of maximum heart rate) and five minutes of cooling down (on treadmill with low speed and without inclination

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: The program include five minutes for warming-up in the form of range of motion and stretching exercises, thirty minutes of walking on treadmill with high speed (60-70% of maximum heart rate) and five minutes of cooling down (on treadmill with low speed and without inclination
Study: NCT05128058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritlecitinib 50 mg
Description: 50 mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritlecitinib 200 mg
Description: 200 mg single dose
Study: NCT04762069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berubicin
Description: Berubicin HCl is a novel synthetic anthracycline with a chemical structure similar to doxorubicin HCl, a cytotoxic anthracycline topoisomerase II inhibitor isolated from cultures of Streptomyces peucetius var. caesius.
Study: NCT06051253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDM-based infliximab intravenous therapy
Description: Infliximab (CT-P13, RemsimaTM) is intravenously given as an induction therapy at a dose of 5 mg/kg at week 0, 2, and 6. From week 14 to 46 (at week 14, 22, 30, 38, and 46), infliximab dose can be increased to 10 mg/kg, targeting trough level (TL) of infliximab 10 mcg/mL or over (If TL is 10 mcg/mL or over under treatment with 5 mg/kg infliximab, 5 mg/kg of infliximab is continued. If TL is lower than 10 mcg/mL, infliximab dose is increased to 10 mg/kg). Once infliximab dose was increased to 10 mg/kg, the next doses are fixed to 10 mg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard infliximab intravenous therapy
Description: Infliximab (CT-P13, RemsimaTM) is intravenously administered at a dose of 5 mg/kg at week 0, 2, 6, 14, 22, 30, 38, and 46. Therapeutic dose monitoring (TDM, checking trough levels of infliximab) is performed at week 14, 22, 30, 38, and 46, but TDM results are not reflected in determining doses of infliximab.
Study: NCT06151756

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Video Supported Mobile Application
Description: The video-supported mobile application was developed to be interactively utilized on smartphones. T